LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase: Completed; Phase 2

Conditions: Non-Hodgkin's Lymphoma

Treatments: Drug: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU

Study type: Interventional

Funder types: Other

Identifiers

NCT00610883

90-042

Details and patient eligibility

About

Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts:

• Induction ends on day 19
• Consolidation ends on day 38 or 42
• Maintenance may include up to 6 cycles

Enrollment: 17 patients

Sex: All

Ages: Under 21 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Non-Hodgkin's Lymphoma stages III, IV, IVA with

  1. T cell lymphomas, any primary site irrespective of LDH level
  2. large cell lymphomas, any primary site irrespective of LDH level
  3. B cell lymphomas, any primary site with initial LDH of less than 500

Exclusion criteria

• B cell lymphomas, any primary site with initial LDH of less than 500 and initial CNS or bone involvement

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

17 participants in 1 patient group

1 - LSA4

Experimental group

Treatment:

Drug: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU